MedTrace Logo

A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets

NCT04550455 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-01-13

No results posted yet for this study

Summary

The purpose of this study is to explore the concept that biomarker sensitivity will detect activity in Multiple Sclerosis (MS) subjects and allow appropriate change in treatment to prevent dysfunction.

Conditions

Interventions

DRUG

Cladribine Tablets

Cladribine tablets will be administered according the current package insert guidelines

Sponsors & Collaborators

  • EMD Serono

    collaborator INDUSTRY

  • Keith Edwards, M.D.

    lead OTHER

Principal Investigators

  • Keith R Edwards, M.D. · MS Center of Northeastern New York, P.C.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-16
Primary Completion
2024-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04550455 on ClinicalTrials.gov